Pharmacie Du Four Bonaparte
HYALEXO CROSS Sodium Hyaluronate Cross-linked 60 mg/3 ml - 1 Syringe 3ml
HYALEXO CROSS is a sterile, non-pyrogenic, resorbable viscoelastic solution made from cross-linked hyaluronic acid of non-animal origin, obtained by bacterial biofermentation, and administered by intra-articular injection. HYALEXO CROSS comes as a colorless gel in a pre-filled, graduated, single-use syringe with a Luer-Lock tip, containing 3 ml of solution.
INDICATIONS Pain and reduced mobility following traumatic or degenerative damage to knee joints and other synovial joints. Non-toxic to animals. MECHANISM OF ACTION Hyaluronic acid is a molecule naturally synthesized by synovial cells. As well as being responsible for the viscoelastic properties of synovial fluid, it contributes to lubrication mechanisms under load and has a protective function. In degenerative joint pathologies, such as chronic primary osteoarthritis, the viscosity of synovial fluid is reduced, which in turn diminishes its ability to lubricate the joint and absorb shocks. Viscosupplementation with hyaluronic acid improves joint mobility and function, reducing the mechanical overload on the joint
Specific References
Give a single injection of HYALEXO CROSS into the joint to be treated. Do not exceed the quantity of one syringe (3 ml) for each injection site and treatment cycle. The beneficial effect of one treatment cycle may last up to 6 months, depending on the severity of symptoms. If additional treatment cycles are required, an interval of 6 months between each treatment is recommended. The effect of HYALEXO CROSS treatment is limited to the joint in which it was administered; the product has no general systemic effect.
INCOMPATIBILITY: hyaluronic acid is incompatible with quaternary ammonium salts such as benzalkonium chloride. It is therefore important to avoid contact between HYALEXO CROSS and these substances
SIDE EFFECTS Joint infiltration with HYALEXO CROSS may cause local side effects, such as pain, warmth, redness and swelling, mainly due to the injection. These symptoms can be relieved by applying ice to the treated area for 5-10 minutes and resting the joint
MODE OF ADMINISTRATION
HYALEXO CROSS should be injected into the joint cavity using an 18-21 G needle. Use a needle of the appropriate length for the joint treatment. Intra-articular infiltration should only be carried out by qualified medical personnel authorized in accordance with current legislation. Take all standard precautions applicable to intra-articular injections. This product should be used with caution in the event of lymphatic or venous stasis in the leg to be treated. In the event of joint effusion, it is recommended to reduce the effusion by aspiration, rest and application of an ice pack. In this case, it is advisable to start treatment with HYALEXO CROSS 2 or 3 days later. Inject the solution contained in HYALEXO CROSS after checking that it is at room temperature. To remove the syringe from its protective blister pack, hold it firmly at body level, without touching the plunger rod. Unscrew the syringe cap and place the needle in the LuerLock connector, screwing it clockwise onto the base until you feel resistance. To ensure safe use of HYALEXO CROSS, it is important to assemble the needle and syringe correctly: if the assembly is not carried out correctly, the needle could detach from the syringe during injection (see Figures 1 and 2). Carefully remove the tip from the syringe, using aseptic technique
Remove the protective cap from the needle just before injecting. Before injecting, expel the air contained in the syringe until a drop of product appears at the needle tip. Inject the product through a perfectly intact area of skin, after removing any residual cosmetic product and disinfecting. Inject only into the synovial space. If necessary, inject under visual control (echo-guidance, radio-guidance), especially when injecting into the hip or shoulder. Ionic or non-ionic contrast media can be used for guidance. Local anaesthesia is recommended prior to intra-articular injection, particularly when the hip is involved. Figure 1 Unscrewing the Luer-Lock cap Figure 2 Inserting the needle
Isabelle J. published the 21/11/2023 following an order made on 09/11/2023
8 sur 10